ViAqua Therapeutics is developing an orally administered RNA particle-based platform that enhances shrimp health by improving resistance to viral diseases, such as WSSV. This solution addresses the significant annual losses of $6 billion in the aquaculture industry caused by viral outbreaks, which can devastate entire shrimp populations within days.
Funding
$8.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Viral diseases, such as White Spot Syndrome Virus (WSSV), cause approximately $6 billion in annual losses to the aquaculture industry, decimating entire shrimp populations within days. Currently, there is no effective method to prevent viral diseases in shrimp.
Solution
ViAqua Therapeutics has developed an orally administered, particle-based RNA platform designed to enhance shrimp health and improve resistance to viral diseases. This delivery platform encapsulates RNA within feed to ensure efficient oral administration and protection of the RNA in the aquatic environment. The encapsulated RNA particles withstand barriers in the digestive system to effectively deliver the RNA. ViAqua's initial product aims to reduce mortality from viral diseases like WSSV.
Target Audience
The primary target audience is shrimp aquaculture farmers seeking to prevent viral disease outbreaks and reduce mortality in their shrimp populations.
Features
- Orally administered RNA particle-based platform
- Encapsulated RNA for protection in aquatic environments
- Efficient delivery of RNA through the shrimp digestive system
- Targets and reduces mortality from viral diseases such as WSSV